Belite Bio, Inc

Healthcare

NASDAQ:BLTE · NASDAQ Capital Market

Market Cap $5.54B Beta -1.24 P/E (TTM) -61.0
$138.16 +0.96%

+$1.31 today

52W Low $56.10High $200.00

Vol 0.15M · Avg 0.17M

EPS (TTM)-$2.26
Biotechnology

Management

Put operating results in leadership context

Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-10.1%

avg 7.6%

ROIC

-10.9%

avg -30.8%

ROA

-9.9%

avg -28.5%

Analysis

ROA is currently the strongest return metric at -9.9% versus its period average of -28.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Management

Key executives, compensation & ownership

Management
NameTitleCompensationTenureAgeShares OwnedOwnership %

Hendrik Scholl

Chief Medical Officer57$10,000.000.02%

Nathan L. Mata

Chief Scientific Officer60$9.00<0.01%

Yu-Hsin Lin

Chairman of the Board of Directors & Chief Executive Officer48$182,949.000.46%

Hao-Yuan Chuang

Chief Financial Officer & Director42$205,264.000.51%

Insider Trading

SEC Form 4 transactions — last 12 months

Management

Buys

0

$0.00

Sells

112

$5.67M

Net Sentiment

$5.67M

Net selling

Most Active

MATA NATHAN L.

103 transactions

DateInsiderTypeSharesPriceValue
May 7, 2026

MATA NATHAN L.

Direct

Sell3$154.61$463.83
May 7, 2026

MATA NATHAN L.

Direct

Sell9$155.25$1,397.28
May 7, 2026

MATA NATHAN L.

Direct

Sell226$152.45$34,453.09
May 7, 2026

MATA NATHAN L.

Direct

Sell428$153.56$65,725.18
May 6, 2026

MATA NATHAN L.

Direct

Sell8$151.57$1,212.56
May 6, 2026

MATA NATHAN L.

Direct

Sell424$152.67$64,732.80
May 6, 2026

MATA NATHAN L.

Direct

Sell128$153.42$19,637.54
May 6, 2026

MATA NATHAN L.

Direct

Sell240$154.41$37,058.81
May 6, 2026

MATA NATHAN L.

Direct

Sell100$155.97$15,597.00
May 6, 2026

MATA NATHAN L.

Direct

Sell100$156.00$15,600.00

1–10 of 112

Analysis

Insiders reported 0 buys worth $0.00 and 112 sells worth $5.67M over the last 12 months. That adds up to net selling of $5.67M. MATA NATHAN L. was the most active insider with 103 transactions.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Who manages BLTE?

Belite Bio, Inc (BLTE) lists 4 active executives. The top listed executive is Hendrik Scholl, Chief Medical Officer.

Are BLTE insiders buying or selling?

Recent insider activity shows net selling of $3.86M.

Explore More

Continue the stock analysis

Jump to another research area for this company.